FDA Approval Fuels Boehringer’s Biosimilar Challenge to AbbVie’s Humira

[cafead]

via The FDA on Wednesday approved a high-concentration and citrate-free version of Boehringer Ingelheim’s Cyltezo (adalimumab-adbm), its interchangeable biosimilar to AbbVie’s blockbuster antirheumatic treatment Humira (adalimumab).

article source